# Galavant Therapeutics, Inc. — Form D

Galavant Therapeutics, Inc. of MENLO PARK, CA, a company, filed a Form D exempt-offering notice with the SEC on 2020-04-01. The offering totals $100K, of which $100K was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2020-04-01
- Form: D
- Accession: 0001808255-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $100K
- Amount sold: $100K
- Investors: 1
- Date of first sale: 2020-03-20
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-364151

## Issuer

- Name: Galavant Therapeutics, Inc.
- CIK: 0001808255
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 155 JEFFERSON DRIVE, SUITE 100, MENLO PARK, CA, 94025
- Phone: 650-268-4252

## Officers, directors & promoters (3)

| Name | Role | Location |
| --- | --- | --- |
| Seth Harrison | Director | Redwood City, CA |
| Jonathan Waldstreicher | Director | Redwood City, CA |
| Jonathan Waldstreicher | Executive Officer | Redwood City, CA |

## More

- [CIK 1808255 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1808255&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001808255-20-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.